Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
InnovAge Holding Corp. stock logo
INNV
InnovAge
$4.20
-0.7%
$3.90
$2.60
$6.69
$571.10M0.5150,852 shs185,428 shs
Intellipharmaceutics International Inc. stock logo
IPCIF
Intellipharmaceutics International
$0.00
$0.00
$0.15
$4.96M1.5312,042 shsN/A
Salarius Pharmaceuticals, Inc. stock logo
SLRX
Salarius Pharmaceuticals
$0.78
+3.0%
$0.83
$0.45
$7.20
$1.61M0.441.56 million shs147,593 shs
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
$42.36
+10.4%
$32.16
$6.76
$130.00
$282.22M2.05963,390 shs1.03 million shs
Wellness Center Usa Inc. stock logo
WCUI
Wellness Center Usa
$0.00
-80.0%
$0.00
$0.00
$0.00
$10K4.8950 shs1,000 shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
InnovAge Holding Corp. stock logo
INNV
InnovAge
-0.71%-5.19%+10.24%+48.94%-16.17%
Intellipharmaceutics International Inc. stock logo
IPCIF
Intellipharmaceutics International
0.00%0.00%0.00%0.00%0.00%
Salarius Pharmaceuticals, Inc. stock logo
SLRX
Salarius Pharmaceuticals
+3.03%-12.47%+5.84%+24.40%-71.60%
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
+10.43%+19.32%+12.24%+150.95%-31.68%
Wellness Center Usa Inc. stock logo
WCUI
Wellness Center Usa
0.00%-81.82%-81.82%0.00%-80.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
InnovAge Holding Corp. stock logo
INNV
InnovAge
0.9928 of 5 stars
1.82.00.00.01.91.70.6
Intellipharmaceutics International Inc. stock logo
IPCIF
Intellipharmaceutics International
N/AN/AN/AN/AN/AN/AN/AN/A
Salarius Pharmaceuticals, Inc. stock logo
SLRX
Salarius Pharmaceuticals
1.2656 of 5 stars
0.05.00.00.03.10.00.6
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
2.6223 of 5 stars
3.52.00.00.01.03.30.6
Wellness Center Usa Inc. stock logo
WCUI
Wellness Center Usa
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
InnovAge Holding Corp. stock logo
INNV
InnovAge
1.50
Reduce$5.0019.05% Upside
Intellipharmaceutics International Inc. stock logo
IPCIF
Intellipharmaceutics International
0.00
N/AN/AN/A
Salarius Pharmaceuticals, Inc. stock logo
SLRX
Salarius Pharmaceuticals
0.00
N/AN/AN/A
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
3.00
Buy$585.001,281.02% Upside
Wellness Center Usa Inc. stock logo
WCUI
Wellness Center Usa
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest TNXP, IPCIF, WCUI, SLRX, and INNV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/3/2025
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
InnovAge Holding Corp. stock logo
INNV
InnovAge
$763.85M0.74N/AN/A$2.04 per share2.06
Intellipharmaceutics International Inc. stock logo
IPCIF
Intellipharmaceutics International
$660K0.00N/AN/A($0.32) per share0.00
Salarius Pharmaceuticals, Inc. stock logo
SLRX
Salarius Pharmaceuticals
N/AN/AN/AN/A$0.95 per shareN/A
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
$10.09M30.90N/AN/A$31.82 per share1.33
Wellness Center Usa Inc. stock logo
WCUI
Wellness Center Usa
$660K0.02N/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
InnovAge Holding Corp. stock logo
INNV
InnovAge
-$21.34M-$0.23N/A70.00N/A-3.75%-11.91%-5.85%9/9/2025 (Estimated)
Intellipharmaceutics International Inc. stock logo
IPCIF
Intellipharmaceutics International
-$2.89M-$0.16N/AN/AN/AN/AN/AN/AN/A
Salarius Pharmaceuticals, Inc. stock logo
SLRX
Salarius Pharmaceuticals
-$5.58M-$4.82N/AN/AN/A-324.13%-174.40%8/8/2025 (Estimated)
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
-$130.04M-$1,963.61N/AN/AN/A-1,313.87%-120.96%-101.28%8/15/2025 (Estimated)
Wellness Center Usa Inc. stock logo
WCUI
Wellness Center Usa
-$750KN/A0.00N/AN/AN/AN/AN/A

Latest TNXP, IPCIF, WCUI, SLRX, and INNV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Salarius Pharmaceuticals, Inc. stock logo
SLRX
Salarius Pharmaceuticals
-$2.40-$1.03+$1.37-$1.03N/AN/A
5/12/2025Q1 2025
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
-$3.23-$2.84+$0.39-$2.84$2.55 million$2.43 million
5/6/2025Q3 2025
InnovAge Holding Corp. stock logo
INNV
InnovAge
-$0.02-$0.08-$0.06-$0.08$214.09 million$218.14 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
InnovAge Holding Corp. stock logo
INNV
InnovAge
N/AN/AN/AN/AN/A
Intellipharmaceutics International Inc. stock logo
IPCIF
Intellipharmaceutics International
N/AN/AN/AN/AN/A
Salarius Pharmaceuticals, Inc. stock logo
SLRX
Salarius Pharmaceuticals
N/AN/AN/AN/AN/A
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
N/AN/AN/AN/AN/A
Wellness Center Usa Inc. stock logo
WCUI
Wellness Center Usa
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
InnovAge Holding Corp. stock logo
INNV
InnovAge
0.04
0.78
0.78
Intellipharmaceutics International Inc. stock logo
IPCIF
Intellipharmaceutics International
N/AN/AN/A
Salarius Pharmaceuticals, Inc. stock logo
SLRX
Salarius Pharmaceuticals
N/A
1.01
1.01
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
N/A
12.31
11.64
Wellness Center Usa Inc. stock logo
WCUI
Wellness Center Usa
N/AN/AN/A
CompanyEmployeesShares OutstandingFree FloatOptionable
InnovAge Holding Corp. stock logo
INNV
InnovAge
2,350135.01 million133.12 millionOptionable
Intellipharmaceutics International Inc. stock logo
IPCIF
Intellipharmaceutics International
1033.09 million32.51 millionNot Optionable
Salarius Pharmaceuticals, Inc. stock logo
SLRX
Salarius Pharmaceuticals
202.13 million2.10 millionNot Optionable
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
507.36 million7.36 millionNot Optionable
Wellness Center Usa Inc. stock logo
WCUI
Wellness Center Usa
8143.19 million120.71 millionNot Optionable

Recent News About These Companies

Flagler Schools cut ribbon on new Wellness Center
Cancer Wellness Center of NEPA holds Annual Walk
Wellness Center attendance up
MCCTC Plans New Health and Wellness Center

New MarketBeat Followers Over Time

Media Sentiment Over Time

InnovAge stock logo

InnovAge NASDAQ:INNV

$4.20 -0.03 (-0.71%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$4.19 -0.01 (-0.24%)
As of 07/10/2025 06:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

InnovAge Holding Corp. manages and provides a range of medical and ancillary services for seniors in need of care and support to live independently in its homes and communities. The company manages its business through Program of All-Inclusive Care for the Elderly (PACE) approach. It also offers in-home care services consisting of skilled, unskilled, and personal care; in-center services, such as primary care, physical therapy, occupational therapy, speech therapy, dental services, mental health and psychiatric services, meals, and activities; transportation to the PACE center and third-party medical appointments; and care management. The company serves participants in the United States; and operates PACE centers in Colorado, California, New Mexico, Pennsylvania, Florida, and Virginia. The company was formerly known as TCO Group Holdings, Inc. and changed its name to InnovAge Holding Corp. in January 2021. InnovAge Holding Corp. was founded in 2007 and is headquartered in Denver, Colorado.

Intellipharmaceutics International stock logo

Intellipharmaceutics International OTCMKTS:IPCIF

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. In addition, it provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. Further, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. Intellipharmaceutics International Inc. was founded in 1998 and is based in Toronto, Canada.

Salarius Pharmaceuticals stock logo

Salarius Pharmaceuticals NASDAQ:SLRX

$0.78 +0.02 (+3.03%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$0.74 -0.04 (-5.01%)
As of 05:31 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.

Tonix Pharmaceuticals stock logo

Tonix Pharmaceuticals NASDAQ:TNXP

$42.36 +4.00 (+10.43%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$42.39 +0.03 (+0.07%)
As of 05:33 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

Wellness Center Usa stock logo

Wellness Center Usa OTCMKTS:WCUI

$0.0001 0.00 (-80.00%)
As of 07/9/2025 09:30 AM Eastern

Wellness Center USA, Inc. engages in the healthcare and medical business in the United States and internationally. The company operates through Medical Devices; and Authentication and Encryption Products and Services segments. It is primarily involved in the marketing and distribution of online sports and nutrition supplements. The company also designs, develops, manufactures, markets, and distributes targeted ultraviolet phototherapy devices that include Psoria-Light, which is used in targeted PUVA photochemistry and UVB phototherapy for the treatment of skin conditions, such as psoriasis, vitiligo, atopic dermatitis, seborrheic dermatitis, and leukoderma. In addition, it offers intelligent microparticles, which provide technologies within the security and supply chain management vertical sectors; and ActiveDuty, a data intelligence service comprising proprietary, unprecedented, and actionable technology, which include a suite of analytical tools, such as artificial intelligence and social psychology for industries, companies, and agencies. The company was incorporated in 2010 and is based in Tucson, Arizona.